Skip to main content

Articles

Page 17 of 62

  2. Individuals with type 2 diabetes mellitus (T2DM) have an increased risk for developing macrovascular disease (MVD) manifested by atherosclerosis. Phenotypically and functionally different monocyte subsets (cla...

    Authors: M. Reijrink, J. van Ark, C. P. H. Lexis, L. M. Visser, M. E. Lodewijk, I. C. C. van der Horst, C. J. Zeebregts, H. van Goor, S. C. A. de Jager, G. Pasterkamp, B. H. R. Wolffenbuttel and J. L. Hillebrands
    Citation: Cardiovascular Diabetology 2022 21:72
    Content type: Research Published on:

  3. Cardiovascular disease (CVD) and nontraumatic lower-limb amputation (LLA) each results in reduced life expectancy in patients with type 1 diabetes, but the differential burden between these conditions is unkno...

    Authors: Marion Camoin, Gilberto Velho, Pierre-Jean Saulnier, Louis Potier, Yawa Abouleka, Charlyne Carpentier, Severine Dubois, Alice Larroumet, Vincent Rigalleau, Elise Gand, Olivier Bourron, Lyse Bordier, André Scheen, Samy Hadjadj, Ronan Roussel, Michel Marre…
    Citation: Cardiovascular Diabetology 2022 21:71
    Content type: Research Published on:

  4. Diabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-related clinical entities. Biomarker profiling emerges as a promising tool for the early diagnosis and risk stratification of either DM...

    Authors: Efstratios Karagiannidis, Dimitrios V. Moysidis, Andreas S. Papazoglou, Eleftherios Panteris, Olga Deda, Nikolaos Stalikas, Georgios Sofidis, Anastasios Kartas, Alexandra Bekiaridou, George Giannakoulas, Helen Gika, George Theodoridis and Georgios Sianos
    Citation: Cardiovascular Diabetology 2022 21:70
    Content type: Research Published on:

  5. Heart failure with reduced ejection fraction (HFrEF) is a major health burden worldwide with high morbidity and mortality. Comorbidities of HFrEF complicate treatment and lead to poor prognosis, among which hy...

    Authors: Ge Zhang, Ke Shi, Wei-Feng Yan, Xue-Ming Li, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2022 21:69
    Content type: Research Published on:

  7. A single measurement of the triglyceride-glucose (TyG) index, a simple and reliable surrogate marker of insulin resistance, is associated with ischemic stroke. However, evidence for an effect of a long-term el...

    Authors: Xianxuan Wang, Baoyu Feng, Zegui Huang, Zefeng Cai, Xinran Yu, Zekai Chen, Zhiwei Cai, Guanzhi Chen, Shouling Wu and Youren Chen
    Citation: Cardiovascular Diabetology 2022 21:66
    Content type: Research Published on:

  8. We examined trends in incidence (2001–2019), clinical characteristics, and in-hospital outcomes following major and minor lower extremity amputations (LEAs) among type 1 diabetes mellitus (T1DM) patients in Sp...

    Authors: Ana Lopez-de-Andres, Rodrigo Jimenez-Garcia, Valentín Hernández-Barrera, Javier de-Miguel-Diez, José M. de-Miguel-Yanes, Ricardo Omaña-Palanco and David Carabantes-Alarcon
    Citation: Cardiovascular Diabetology 2022 21:65
    Content type: Research Published on:

  9. Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other ...

    Authors: Mansoor Husain, Agostino Consoli, Alessandra De Remigis, Anna Sina Pettersson Meyer, Søren Rasmussen and Stephen Bain
    Citation: Cardiovascular Diabetology 2022 21:64
    Content type: Research Published on:

  10. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been o...

    Authors: Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H. H. Kramer, Max Nieuwdorp and Richard G. IJzerman
    Citation: Cardiovascular Diabetology 2022 21:63
    Content type: Research Published on:

  11. Atherosclerotic cardiovascular diseases (CVD) is the leading cause of death in diabetes, but the full range of biomarkers reflecting atherosclerotic burden and CVD risk in people with diabetes is unknown. Meta...

    Authors: Zhe Huang, Lucija Klaric, Justina Krasauskaite, Stela McLachlan, Mark W. J. Strachan, James F. Wilson and Jackie F. Price
    Citation: Cardiovascular Diabetology 2022 21:62
    Content type: Research Published on:

  12. Individuals with type 2 diabetes have a substantially elevated cardiovascular risk. A higher plasma phosphate level promotes vascular calcification, which may adversely affect outcomes in individuals with type...

    Authors: Amarens van der Vaart, Qingqing Cai, Ilja M. Nolte, André P. J. van Beek, Gerjan Navis, Stephan J. L. Bakker, Peter R. van Dijk and Martin H. de Borst
    Citation: Cardiovascular Diabetology 2022 21:61
    Content type: Research Published on:

  13. Sleep duration is associated with mortality. However, prior studies exploring whether sleep duration predicts subsequent long-term mortality in patients with diabetes are limited. This study aims to examine wh...

    Authors: Chia-Ing Li, Cheng-Chieh Lin, Chiu-Shong Liu, Chih-Hsueh Lin, Shing-Yu Yang and Tsai-Chung Li
    Citation: Cardiovascular Diabetology 2022 21:60
    Content type: Research Published on:

  14. We aimed to study the cumulative incidence and risk factors (sex, age, calendar year of diabetes onset, country of origin and educational level) of acute myocardial infarction (AMI) in subjects with type 1 dia...

    Authors: Maryam Saeed, Lars C. Stene, Inger Ariansen, Grethe S. Tell, German Tapia, Geir Joner and Torild Skrivarhaug
    Citation: Cardiovascular Diabetology 2022 21:59
    Content type: Research Published on:

  15. Evidence to guide type 2 diabetes treatment individualization is limited. We evaluated heterogeneous treatment effects (HTE) of intensive glycemic control in type 2 diabetes patients on major adverse cardiovas...

    Authors: Justin A. Edward, Kevin Josey, Gideon Bahn, Liron Caplan, Jane E. B. Reusch, Peter Reaven, Debashis Ghosh and Sridharan Raghavan
    Citation: Cardiovascular Diabetology 2022 21:58
    Content type: Research Published on:

  16. Greater efforts are needed to overcome the worldwide reported low achievement of LDL-c targets. This survey aimed to dissect whether and how the physician-based evaluation of patients with diabetes is associat...

    Authors: Mario Luca Morieri, Olga Lamacchia, Enzo Manzato, Andrea Giaccari and Angelo Avogaro
    Citation: Cardiovascular Diabetology 2022 21:57
    Content type: Research Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2022 21:73

  17. Considering the nature of diabetes mellitus (DM) in coronary artery disease, it is unclear whether complete revascularization is beneficial or not in patients with DM. We investigated the clinical impact of an...

    Authors: Doyeon Hwang, Jiesuck Park, Han-Mo Yang, Seokhun Yang, Jeehoon Kang, Jung-Kyu Han, Kyung Woo Park, Hyun-Jae Kang, Bon-Kwon Koo and Hyo-Soo Kim
    Citation: Cardiovascular Diabetology 2022 21:56
    Content type: Research Published on:

  18. Insulin resistance is a risk factor for cardiovascular disease. Recently, we have developed a novel index, FLAIS (Fasting Laboratory Assessment of Insulin Sensitivity), which accurately reflects insulin sensit...

    Authors: Monika Karczewska-Kupczewska, Agnieszka Nikołajuk, Marcin Kondraciuk, Zofia Stachurska, Marlena Dubatówka, Anna Szpakowicz, Marek Strączkowski, Irina Kowalska and Karol Kamiński
    Citation: Cardiovascular Diabetology 2022 21:55
    Content type: Research Published on:

  19. Mildly elevated bilirubin, a by-product of hemoglobin breakdown, might mitigate cardiometabolic risk factors including adiposity, dyslipidemia, and high blood pressure (BP). We investigated the cross-sectional...

    Authors: Nazlisadat Seyed Khoei, Karl-Heinz Wagner, Anja M. Sedlmeier, Marc J. Gunter, Neil Murphy and Heinz Freisling
    Citation: Cardiovascular Diabetology 2022 21:54
    Content type: Research Published on:

  20. Although both type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are associated with increased risk of cardiovascular disease (CVD), evidence is lacking as to whether the presence of ...

    Authors: Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2022 21:53
    Content type: Research Published on:

  21. The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate mark...

    Authors: Mi-Hyang Jung, Sang-Wook Yi, Sang Joon An, Jee-Jeon Yi, Sang-Hyun Ihm, Seongwoo Han, Kyu-Hyung Ryu, Hae Ok Jung and Ho-Joong Youn
    Citation: Cardiovascular Diabetology 2022 21:52
    Content type: Research Published on:

  22. Glucagon like peptide-1 receptor agonists (GLP-1RAs) have shown to reduce mortality and cardiovascular events in patients with type 2 diabetes mellitus (T2DM). Since the impairment in number and function of va...

    Authors: Annalisa Sforza, Vera Vigorelli, Erica Rurali, Gianluca Lorenzo Perrucci, Elisa Gambini, Martina Arici, Alessia Metallo, Raffaella Rinaldi, Paolo Fiorina, Andrea Barbuti, Angela Raucci, Elena Sacco, Marcella Rocchetti, Giulio Pompilio, Stefano Genovese and Maria Cristina Vinci
    Citation: Cardiovascular Diabetology 2022 21:51
    Content type: Original investigation Published on:

  23. The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference co...

    Authors: Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J. L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić…
    Citation: Cardiovascular Diabetology 2022 21:50
    Content type: Commentary Published on:

  24. Metformin has favorable effects on cardiovascular outcomes in both newly onset and advanced type 2 diabetes, as previously reported findings from the UK Prospective Diabetes Study and the HOME trial have demon...

    Authors: Johanna M. G. Stultiens, Wiebe M. C. Top, Dorien M. Kimenai, Philippe Lehert, Otto Bekers, Coen D. A. Stehouwer, Adriaan Kooy and Steven J. R. Meex
    Citation: Cardiovascular Diabetology 2022 21:49
    Content type: Original investigation Published on:

  25. Stress hyperglycemia is a strong predictor of adverse outcomes in patients with acute myocardial infarction (AMI). Recently, the stress hyperglycemia ratio (SHR) has been designed as an index to identify acute...

    Authors: Wei Xu, Yan-min Yang, Jun Zhu, Shuang Wu, Juan Wang, Han Zhang and Xing-hui Shao
    Citation: Cardiovascular Diabetology 2022 21:48
    Content type: Original investigation Published on:

  26. We conducted a systematic review and meta-analysis of the cardiovascular, kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among patients with diabetic kidney disease (DKD).

    Authors: Arnaud D. Kaze, Min Zhuo, Seoyoung C. Kim, Elisabetta Patorno and Julie M. Paik
    Citation: Cardiovascular Diabetology 2022 21:47
    Content type: Original investigation Published on:

  27. Inflammation plays a crucial role in coronary atherosclerosis progression, and growing evidence has demonstrated that the fibrinogen-to-albumin ratio (FAR), as a novel inflammation biomarker, is associated wit...

    Authors: Peizhi Wang, Deshan Yuan, Ce Zhang, Pei Zhu, Sida Jia, Ying Song, Xiaofang Tang, Jingjing Xu, Tianyu Li, Guyu Zeng, Xueyan Zhao, Yuejin Yang, Bo Xu, Runlin Gao and Jinqing Yuan
    Citation: Cardiovascular Diabetology 2022 21:46
    Content type: Research Published on:

  28. Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure patients. These inhibitors have on-target (SGLT2 ...

    Authors: Sha Chen, Ruben Coronel, Markus W. Hollmann, Nina C. Weber and Coert J. Zuurbier
    Citation: Cardiovascular Diabetology 2022 21:45
    Content type: Review Published on:

  29. Pericoronary adipose tissue (PCAT) attenuation on coronary computed tomography angiography (CTA) is a non-invasive biomarker for pericoronary inflammation. We aimed to investigate the prognostic value of PCAT ...

    Authors: Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Mitsutaka Nakashima, Takashi Miki, Takahiro Nishihara, Hironobu Toda, Masatoki Yoshida and Hiroshi Ito
    Citation: Cardiovascular Diabetology 2022 21:44
    Content type: Original investigation Published on:

  30. Triglyceride glucose (TyG) index was recently reported to be associated with an increased risk of the development and recurrence of cardiovascular events, and atherosclerosis is a main speculative mechanism. H...

    Authors: Mengyuan Miao, Guo Zhou, Anran Bao, Yaming Sun, Huaping Du, Liyan Song, Yongjun Cao, Shoujiang You and Chongke Zhong
    Citation: Cardiovascular Diabetology 2022 21:43
    Content type: Original investigation Published on:

  31. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorena...

    Authors: Dario Giugliano, Miriam Longo, Simona Signoriello, Maria Ida Maiorino, Bruno Solerte, Paolo Chiodini and Katherine Esposito
    Citation: Cardiovascular Diabetology 2022 21:42
    Content type: Original investigation Published on:

  32. New onset diabetes after transplantation (NODAT) is a frequent and serious complication of renal transplantation resulting in worse graft and patient outcomes. The pathophysiology of NODAT is incompletely unde...

    Authors: Tamas Szili-Torok, Sara Sokooti, Maryse C. J. Osté, Antonio W. Gomes-Neto, Robin P. F. Dullaart, Stephan J. L. Bakker and Uwe J. F. Tietge
    Citation: Cardiovascular Diabetology 2022 21:41
    Content type: Original investigation Published on:

  33. Distinguishable sex differences exist in fat mass and muscle mass. High fat mass and low muscle mass are independently associated with cardiovascular disease (CVD) risk factors in people living with type 2 dia...

    Authors: Tasuku Terada, Jennifer L. Reed, Sol Vidal-Almela, Matheus Mistura, Kentaro Kamiya and Kimberley L. Way
    Citation: Cardiovascular Diabetology 2022 21:40
    Content type: Original investigation Published on:

  34. Atrial fibrillation (AF) and diabetes mellitus (DM) constitute two major closely inter-related chronic cardiovascular disorders whose concurrent prevalence rates are steadily increasing. Although, the pathogen...

    Authors: Andreas S. Papazoglou, Anastasios Kartas, Dimitrios V. Moysidis, Christos Tsagkaris, Stavros P. Papadakos, Alexandra Bekiaridou, Athanasios Samaras, Efstratios Karagiannidis, Marios Papadakis and George Giannakoulas
    Citation: Cardiovascular Diabetology 2022 21:39
    Content type: Review Published on:

  35. The triglyceride glucose (TyG) index serves as a surrogate indicator of insulin resistance. However, there is limited evidence on the association between the TyG index and carotid artery plaque (CAP) in patien...

    Authors: Zhu Li, Yuanyuan He, Shuo Wang, Lin Li, Rongrong Yang, Yijia Liu, Qi Cheng, Lu Yu, Yanchao Zheng, Hongmei Zheng, Shan Gao and Chunquan Yu
    Citation: Cardiovascular Diabetology 2022 21:38
    Content type: Original investigation Published on:

  36. Type 2 diabetes mellitus causes left ventricular (LV) remodeling and increases the risk of aortic regurgitation (AR), which causes further heart damage. This study aimed to investigate whether AR aggravates LV...

    Authors: Li-Ting Shen, Li Jiang, Ya-Wen Zhu, Meng-Ting Shen, Shan Huang, Rui Shi, Yuan Li and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2022 21:37
    Content type: Original investigation Published on:

  37. Soluble suppression of tumorigenesis-2 (sST2) and galectin (Gal)-3 are two biomarkers related to inflammation, metabolic disturbances and to myocardial fibrosis that characterize several cardiac pathological c...

    Authors: Paola Simeone, Romina Tripaldi, Annika Michelsen, Thor Ueland, Rossella Liani, Sonia Ciotti, Kåre I. Birkeland, Hanne L. Gulseth, Augusto Di Castelnuovo, Francesco Cipollone, Pål Aukrust, Agostino Consoli, Bente Halvorsen and Francesca Santilli
    Citation: Cardiovascular Diabetology 2022 21:36
    Content type: Original investigation Published on:

  38. The prevalence of prediabetes is increasing in the global population and its metabolic derangements may expose to a higher risk to develop type 2 diabetes (T2D) and its cardiovascular burden. Lifestyle modific...

    Authors: Lucia La Sala, Elena Tagliabue, Simona Mrakic-Sposta, Anna Chiara Uccellatore, Pamela Senesi, Ileana Terruzzi, Emilio Trabucchi, Luigi Rossi-Bernardi and Livio Luzi
    Citation: Cardiovascular Diabetology 2022 21:35
    Content type: Original investigation Published on:

  39. Plasma growth differentiation factor-15 (GDF-15) biomarker levels increase in response to inflammation and tissue injury, and increased levels of GDF-15 are associated with increased risk of mortality in patie...

    Authors: Massar Omar, Jesper Jensen, Caroline Kistorp, Kurt Højlund, Lars Videbæk, Christian Tuxen, Julie H. Larsen, Camilla F. Andersen, Finn Gustafsson, Lars Køber, Morten Schou and Jacob Eifer Møller
    Citation: Cardiovascular Diabetology 2022 21:34
    Content type: Original investigation Published on:

  40. The triglyceride-glucose index (TyG index) has emerged as a reliable surrogate marker of insulin resistance associated with arterial stiffness. However, most studies were based on a cross-sectional design, and...

    Authors: Yu Yan, Dan Wang, Yue Sun, Qiong Ma, Keke Wang, Yueyuan Liao, Chen Chen, Hao Jia, Chao Chu, Wenling Zheng, Jiawen Hu, Yue Yuan, Yang Wang, Yuliang Wu and Jianjun Mu
    Citation: Cardiovascular Diabetology 2022 21:33
    Content type: Original investigation Published on:

  41. The association between visceral adiposity index (VAI) and diabetic complications has been reported in cross-sectional studies, while the effect of VAI on complication development remains unclear. This study a...

    Authors: Zhiyuan Wu, Siqi Yu, Xiaoping Kang, Yue Liu, Zongkai Xu, Zhiwei Li, Jinqi Wang, Xinlei Miao, Xiangtong Liu, Xia Li, Jingbo Zhang, Wei Wang, Lixin Tao and Xiuhua Guo
    Citation: Cardiovascular Diabetology 2022 21:32
    Content type: Original investigation Published on:

  42. Type 2 diabetes (T2D) is associated with coronary microvascular dysfunction, which is thought to contribute to compromised diastolic function, ultimately culminating in heart failure with preserved ejection fr...

    Authors: Shawn Veitch, Makon-Sébastien Njock, Mark Chandy, M. Ahsan Siraj, Lijun Chi, HaoQi Mak, Kai Yu, Kumaragurubaran Rathnakumar, Carmina Anjelica Perez-Romero, Zhiqi Chen, Faisal J. Alibhai, Dakota Gustafson, Sneha Raju, Ruilin Wu, Dorrin Zarrin Khat, Yaxu Wang…
    Citation: Cardiovascular Diabetology 2022 21:31
    Content type: Original investigation Published on:

  43. Coronary artery disease (CAD) confers considerable morbidity and mortality in diabetes. However, the role of CAD in additive effect of left ventricular (LV) function has rarely been explored in type 2 diabetes...

    Authors: Jin Wang, Yuan Li, Ying-Kun Guo, Shan Huang, Rui Shi, Wei-Feng Yan, Wen-Lei Qian, Guang-Xi He and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2022 21:30
    Content type: Original investigation Published on:

  44. Non-diabetic coronary artery disease (CAD) patients are thought to encounter metabolic dysfunction and while these changes may be imperceptible to the patient they probably influence outcomes. At present, ther...

    Authors: Yitian Zheng, Chen Li, Jie Yang, Samuel Seery, Yu Qi, Wenyao Wang, Kuo Zhang, Chunli Shao and Yi-Da Tang
    Citation: Cardiovascular Diabetology 2022 21:29
    Content type: Original investigation Published on:

  45. Current guidelines recommend life-long use of statin for patients with type 2 diabetes (T2D), however, a number of patients discontinue statin therapy in clinical practice. We aimed to estimate the optimal sta...

    Authors: Ji Yoon Kim, Jimi Choi, Sin Gon Kim and Nam Hoon Kim
    Citation: Cardiovascular Diabetology 2022 21:28
    Content type: Original investigation Published on:

  46. Empagliflozin can curb inflammation and oxidative stress, through sodium-proton exchanger (NHE) inhibition, in a model of lipotoxicity in human myeloid angiogenic cells (MAC), which mediate endothelial repairi...

    Authors: Gloria Cinquegrani, Valentina Spigoni, Federica Fantuzzi, Riccardo C. Bonadonna and Alessandra Dei Cas
    Citation: Cardiovascular Diabetology 2022 21:27
    Content type: Original investigation Published on:

  47. Iron stores, estimated as ferritin levels, and type 2 diabetes (T2D) have been associated previously, while findings regarding coronary heart disease (CHD) and cerebrovascular disease (CEVD) are still inconclu...

    Authors: Milton-Fabian Suárez-Ortegón, Stela McLachlan, José-Manuel Fernandez-Real, Tomi-Pekka Tuomainen, Alex Aregbesola and Sarah H. Wild
    Citation: Cardiovascular Diabetology 2022 21:26
    Content type: Original investigation Published on:

  48. Altered adipokine secretion in dysfunctional adipose tissue facilitates the development of atherosclerotic diseases including lower extremity peripheral artery disease (PAD). Asprosin is a recently identified ...

    Authors: Mei You, Yushuang Liu, Bowen Wang, Li Li, Hexuan Zhang, Hongbo He, Qing Zhou, Tingbing Cao, Lijuan Wang, Zhigang Zhao, Zhiming Zhu, Peng Gao and Zhencheng Yan
    Citation: Cardiovascular Diabetology 2022 21:25
    Content type: Original investigation Published on:

  49. Pre-existing cardiometabolic comorbidities place SARS-CoV-2 positive patients at a greater risk for poorer clinical course and mortality than those without it. We aimed to analyze real-world registry data focu...

    Authors: Parth Shah, Kim Magee, Kiara H. Buccellato, McKenna Ismond and Jalisa Watson
    Citation: Cardiovascular Diabetology 2022 21:24
    Content type: Original investigation Published on:

  50. Restenosis, defined as the re-narrowing of an arterial lumen after revascularization, represents an increasingly important issue in clinical practice. Indeed, as the number of stent placements has risen to an ...

    Authors: Scott Wilson, Pasquale Mone, Urna Kansakar, Stanislovas S. Jankauskas, Kwame Donkor, Ayobami Adebayo, Fahimeh Varzideh, Michael Eacobacci, Jessica Gambardella, Angela Lombardi and Gaetano Santulli
    Citation: Cardiovascular Diabetology 2022 21:23
    Content type: Review Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions 

Cardiovascular Diabetology

ISSN: 1475-2840